LivaNova: FDA 510(k) clearances across all its applicant names
FDA lists 219 510(k) clearances, 4 PMA and 0 De Novo decisions across the 14 applicant names Caduvo groups under LivaNova, first 1979, latest 2026. Median 510(k) review time across these names: 90 days. Since 2017 the median was 124 days, against 146 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 7 | 90 |
| 2013 | 5 | 33 |
| 2014 | 3 | 29 |
| 2015 | 2 | 120 |
| 2016 | 0 | — |
| 2017 | 3 | 258 |
| 2018 | 3 | 30 |
| 2019 | 2 | 86 |
| 2020 | 4 | 170 |
| 2021 | 4 | 106 |
| 2022 | 1 | 257 |
| 2023 | 4 | 191 |
| 2024 | 6 | 96 |
| 2025 | 6 | 144 |
| 2026 | 4 | 86 |
The 14 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| Sorin Group Italia S.R.L. | 63 | 0 | 0 | 1995–2026 |
| Cobe Cardiovascular, Inc. | 43 | 0 | 0 | 1992–2005 |
| Carbomedics, Inc. | 22 | 1 | 0 | 1979–1997 |
| Sorin Biomedica, Fiat, USA, Inc. | 20 | 0 | 0 | 1980–1994 |
| Sorin Group Deutschland GmbH | 20 | 0 | 0 | 2006–2017 |
| Sorin Biomedical, Inc. | 15 | 0 | 0 | 1993–1999 |
| Stockert Instrumente GmbH | 9 | 0 | 0 | 2001–2004 |
| Sulzer Carbomedics, Inc. | 8 | 0 | 0 | 1998–2002 |
| Livanova Deutschland, GmbH | 7 | 0 | 0 | 2020–2023 |
| Stockert GmbH | 5 | 0 | 0 | 2001–2007 |
| LivaNova USA, Inc. | 3 | 2 | 0 | 2024–2026 |
| Sorin Group USA, Inc. | 2 | 1 | 0 | 2010–2013 |
| Cyberonics, Inc. | 1 | 0 | 0 | 2009–2009 |
| Sorin Biomedica Cardio S.R.L. | 1 | 0 | 0 | 2007–2007 |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 124 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 146 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| DTZ | Oxygenator, Cardiopulmonary Bypass | 33 | 33 |
| DTN | Reservoir, Blood, Cardiopulmonary Bypass | 25 | 25 |
| DWF | Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass | 22 | 22 |
| CAC | Apparatus, Autotransfusion | 16 | 16 |
| DTQ | Console, Heart-Lung Machine, Cardiopulmonary Bypass | 14 | 14 |
| DTM | Filter, Blood, Cardiopulmonary Bypass, Arterial Line | 12 | 12 |
| KRH | Ring, Annuloplasty | 7 | 7 |
| DWA | Control, Pump Speed, Cardiopulmonary Bypass | 6 | 6 |
| DSY | Prosthesis, Vascular Graft, Of 6mm And Greater Diameter | 5 | 5 |
| DTR | Heat-Exchanger, Cardiopulmonary Bypass | 5 | 5 |
Plus 50 more product codes.
Review panels
- Cardiovascular (189)
- Clinical Chemistry (10)
- Anesthesiology (6)
- Dental (5)
- Orthopedic (5)
- Gastroenterology and Urology (2)
- Neurology (2)
- General and Plastic Surgery (2)
- Ophthalmic (1)
- Clinical Toxicology (1)
Most recent LivaNova 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K263092 | Dual Stage Venous Cannulae | Sorin Group Italia S.R.L. | DWF | 2026-10-01 | 28 |
| K262052 | Tri Stage Venous Cannulae | Sorin Group Italia S.R.L. | DWF | 2026-09-28 | 102 |
| K250937 | Venous Return Cannulae | LivaNova USA, Inc. | DWF | 2026-03-11 | 348 |
| K253671 | Dual Stage Venous Cannulae | Sorin Group Italia S.R.L. | DWF | 2026-01-30 | 70 |
| K251783 | Inspire HCR and HCR DUAL cardiotomy reservoirs | Sorin Group Italia S.R.L. | DTN | 2025-12-22 | 194 |
| K253616 | ProtekDilate Vascular Access Kit | Sorin Group Italia S.R.L. | DRE | 2025-12-19 | 31 |
| K250283 | RAP Femoral Venous Cannulae | LivaNova USA, Inc. | DWF | 2025-07-10 | 160 |
| K250610 | Easyflow (103-200; 103-300); Easyflow Duo (103-210; 103-310) | Sorin Group Italia S.R.L. | DWF | 2025-06-27 | 119 |
| K250150 | VANGUARD Blood cardioplegia Systems (Vanguard 4:1 Blood cardioplegia set); VANGUARD Blood cardioplegia Systems (Vanguard 4:1 Blood cardioplegia set with shunt); VANGUARD Blood cardioplegia Systems (Vanguard 4:1 Blood Cardioplegia Set Mini) | Sorin Group Italia S.R.L. | DTR | 2025-05-30 | 129 |
| K243264 | DHF 0.2 Hemoconcentrator (DHF 02); DHF 0.6 Hemoconcentrator (DHF 06); SH 14 Hemoconcentrator (SH 14) | Sorin Group Italia S.R.L. | KDI | 2025-04-25 | 192 |
209 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P250013 | PMA | aura6000 system | 2026-03-18 |
| P970003 | PMA | VNS THERAPY SYSTEM | 1997-07-16 |
| P890045 | PMA | GELSEAL TM TRIAXIAL VASCULAR GRAFT | 1993-01-11 |
| P850063 | PMA | MICRO YAG ND:YAG LASER SYSTEM | 1986-01-31 |
Recalls
249 product recalls in 85 recall events under these names; 8 initiated in the last five years.
10 product recalls in 4 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 0 initiated in the last five years. Most often: Nellcor Puritan Bennett Inc. (dba Covidien Ltd) (5), Vascutek, Ltd. (4), Zimmer Inc. (1).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 20 device studies (0 active or recruiting) with an industry lead sponsor under the 2 sponsor names below. Most recent:
- NCT02545582: VITARIA Registry Study (Cyberonics, Inc.; Suspended, started 2015-08)
- NCT02385526: Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation (Cyberonics, Inc.; Completed, started 2015-04-28)
- NCT03163030: Autonomic Regulation Therapy in Heart Failure With Preserved Ejection Fraction (Cyberonics, Inc.; Completed, started 2014-08)
- NCT01846741: VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37) (Cyberonics, Inc.; Completed, started 2013-07)
- NCT01810679: Perceval S Aortic Heart Valve Study- North America (Sorin Group USA, Inc.; Terminated, started 2013-04)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| Cyberonics, Inc. | 14 |
| Sorin Group USA, Inc. | 6 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
Parent company SEC filings
LivaNova PLC (LIVN): EDGAR filings, CIK 1639691. The parent's SEC registrant is entered by hand for this group, not matched by name.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
LivaNova was formed from the 2015 merger of Sorin and Cyberonics. Sorin had acquired COBE Cardiovascular and Carbomedics. Includes filings made before each acquisition.
Sources
- https://en.wikipedia.org/wiki/LivaNova
- https://www.sec.gov/Archives/edgar/data/864683/000086468315000054/form8-k.htm
Frequently asked questions
How many FDA 510(k) clearances are listed across LivaNova's applicant names?
FDA lists 219 510(k) clearances, 4 PMA and 0 De Novo decisions across the 14 applicant names Caduvo groups under LivaNova, first 1979, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does LivaNova file under?
The names with the most 510(k) clearances in this group are Sorin Group Italia S.R.L. (63); Cobe Cardiovascular, Inc. (43); Carbomedics, Inc. (22); Sorin Biomedica, Fiat, USA, Inc. (20); Sorin Group Deutschland GmbH (20). The full list of 14 names is on this page.
How long does FDA take to clear LivaNova 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 90 days. Since 2017 the median was 124 days, against 146 days for all cleared 510(k)s in the same product codes.
Does the LivaNova count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does LivaNova sponsor?
ClinicalTrials.gov lists 20 device studies (0 active or recruiting) with an industry lead sponsor under 2 sponsor names Caduvo groups under LivaNova. ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 219 LivaNova clearances with predicates and recalls
- Run predicate analysis for product code DTZ, LivaNova's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup